Roth Capital Upgrades Celldex Therapeutics (CLDX) to Buy
Tweet
Share
E-mailGet Alerts CLDX Hot Sheet
Price: $37.44 --0%
Rating Summary:
18 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 9 | New: 5
Rating Summary:
18 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 9 | New: 5
Join SI Premium – FREE
Roth Capital upgraded Celldex Therapeutics (NASDAQ: CLDX) from Neutral to Buy, price target raised from $3 to $6.
For an analyst ratings summary and ratings history on Celldex Therapeutics click here. For more ratings news on Celldex Therapeutics click here.
Shares of Celldex Therapeutics closed at $3.15 yesterday.
For an analyst ratings summary and ratings history on Celldex Therapeutics click here. For more ratings news on Celldex Therapeutics click here.
Shares of Celldex Therapeutics closed at $3.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Upgrades Watts Waters (WTS) to Overweight
- Daiwa Securities Upgrades Honeywell International (HON) to Outperform (2)
- Roth/MKM Upgrades VersaBank (VBNK) to Buy
Create E-mail Alert Related Categories
UpgradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
